These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34980142)

  • 1. Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies.
    Dillinger T; Sheibani-Tezerji R; Pulverer W; Stelzer I; Hassler MR; Scheibelreiter J; Pérez Malla CU; Kuroll M; Domazet S; Redl E; Ely S; Brezina S; Tiefenbacher A; Rebhan K; Hübner N; Grubmüller B; Mitterhauser M; Hacker M; Weinhaeusel A; Simon J; Zeitlinger M; Gsur A; Kramer G; Shariat SF; Kenner L; Egger G
    Mol Cancer; 2022 Jan; 21(1):7. PubMed ID: 34980142
    [No Abstract]   [Full Text] [Related]  

  • 2. Non-invasive lung cancer diagnosis and prognosis based on multi-analyte liquid biopsy.
    Chen K; Sun J; Zhao H; Jiang R; Zheng J; Li Z; Peng J; Shen H; Zhang K; Zhao J; Zhu S; Wang Y; Yang F; Wang J
    Mol Cancer; 2021 Jan; 20(1):23. PubMed ID: 33514352
    [No Abstract]   [Full Text] [Related]  

  • 3. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.
    Beltran H; Romanel A; Conteduca V; Casiraghi N; Sigouros M; Franceschini GM; Orlando F; Fedrizzi T; Ku SY; Dann E; Alonso A; Mosquera JM; Sboner A; Xiang J; Elemento O; Nanus DM; Tagawa ST; Benelli M; Demichelis F
    J Clin Invest; 2020 Apr; 130(4):1653-1668. PubMed ID: 32091413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment.
    Boerrigter E; Benoist GE; van Oort IM; Verhaegh GW; van Hooij O; Groen L; Smit F; Oving IM; de Mol P; Smilde TJ; Somford DM; Mehra N; Schalken JA; van Erp NP
    Mol Oncol; 2021 Sep; 15(9):2453-2465. PubMed ID: 33650292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics of androgen signaling in prostate cancer: Focus on castration resistance and predictive biomarkers of response to treatment.
    Del Re M; Crucitta S; Restante G; Rofi E; Arrigoni E; Biasco E; Sbrana A; Coppi E; Galli L; Bracarda S; Santini D; Danesi R
    Crit Rev Oncol Hematol; 2018 May; 125():51-59. PubMed ID: 29650277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Biomarkers in metastatic castration-resistant prostate cancer].
    Miller K
    Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of AR-V7 in Liquid Biopsies of Castrate Resistant Prostate Cancer Patients: A Comparison of AR-V7 Analysis in Circulating Tumor Cells, Circulating Tumor RNA and Exosomes.
    Nimir M; Ma Y; Jeffreys SA; Opperman T; Young F; Khan T; Ding P; Chua W; Balakrishnar B; Cooper A; De Souza P; Becker TM
    Cells; 2019 Jul; 8(7):. PubMed ID: 31288377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer.
    Mollica V; Di Nunno V; Santoni M; Cimadamore A; Scarpelli M; Lopez-Beltran A; Cheng L; Mariani C; Battelli N; Montironi R; Massari F
    Expert Rev Mol Diagn; 2020 Feb; 20(2):207-217. PubMed ID: 31640441
    [No Abstract]   [Full Text] [Related]  

  • 9. AR-V7 Transcripts in Whole Blood RNA of Patients with Metastatic Castration Resistant Prostate Cancer Correlate with Response to Abiraterone Acetate.
    Todenhöfer T; Azad A; Stewart C; Gao J; Eigl BJ; Gleave ME; Joshua AM; Black PC; Chi KN
    J Urol; 2017 Jan; 197(1):135-142. PubMed ID: 27436429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic Power of DNA Methylation Classifiers for Early Detection of Cancer.
    Roy D; Tiirikainen M
    Trends Cancer; 2020 Feb; 6(2):78-81. PubMed ID: 32061307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.
    Buonerba C; Di Lorenzo G; Sonpavde G
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1113-1120. PubMed ID: 27665838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive biomarkers in metastatic castration-resistant prostate cancer.
    Armstrong AJ
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):184-188. PubMed ID: 28398272
    [No Abstract]   [Full Text] [Related]  

  • 13. DNA methylation detection technology and plasma-based methylation biomarkers in screening of gastrointestinal carcinoma.
    Cao M; Zhang C; Zhou L
    Epigenomics; 2021 Aug; 13(16):1327-1339. PubMed ID: 34369810
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on our ability to monitor castration-resistant prostate cancer dynamics with cell-free DNA.
    Conteduca V; Brighi N; Conteduca D; Bleve S; Gianni C; Schepisi G; Iaia ML; Gurioli G; Lolli C; De Giorgi U
    Expert Rev Mol Diagn; 2021 Jul; 21(7):631-640. PubMed ID: 34043486
    [No Abstract]   [Full Text] [Related]  

  • 15. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
    Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
    Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study.
    Benoist GE; van Oort IM; Boerrigter E; Verhaegh GW; van Hooij O; Groen L; Smit F; de Mol P; Hamberg P; Dezentjé VO; Mehra N; Gerritsen W; Somford DM; van Erp NPH; Schalken JA
    Clin Chem; 2020 Jun; 66(6):842-851. PubMed ID: 32408351
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
    Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.
    Yu J; Cho E; Choi J; Lim JE; Lee J; Kang M; Sung HH; Jeong BC; Seo SI; Jeon SS; Lee HM; Jeon HG
    Investig Clin Urol; 2021 Mar; 62(2):224-232. PubMed ID: 33660451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.
    VanderWeele DJ
    Clin Adv Hematol Oncol; 2015 Sep; 13(9):580-3. PubMed ID: 26452188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.